Injectable Myocardial Matrix Hydrogel Mitigates Negative Left Ventricular Remodeling in a Chronic Myocardial Infarction Model

Figures

• 

  Figure 1. QconCAT Quantification of Myocardial Matrix Hydrogel The pie chart shows the average percentage of ECM, ECM-associated, and cellular contaminant protein content as determined using targeted ECM proteomics. ECM = extracellular matrix; QconCAT = quantitative concatamer.

• 

  Figure 2. Timeline of Chronic MI Animal Model Showing Long-Term and Short-Term Time Points Image created with BioRender (Toronto, Ontario, Canada). MI = myocardial infarction; MRI = magnetic resonance imaging; SD = Sprague Dawley.

• 

  Figure 3. CMR of the Myocardial Matrix Hydrogel Cardiac magnetic resonance (CMR) imaging shows the myocardial matrix hydrogel preserves LV volumes and improves cardiac wall thickening up to 4 weeks post-injection. Representative MR images of saline control (A) and matrix-treated (B) animals at 4 weeks post-injection are shown at end systole (left) and end diastole (right). MR images were used to determine changes in (C) LV ESV and (D) LV EDV from baseline (2 days pre-injection, 8 weeks post-MI) and 4 weeks post-injection (12 weeks post-MI). (E) Change in wall thickening from baseline to 4 weeks post-injection (Δwall thickening) shows the matrix group was significantly greater than saline controls. ∗p < 0.05 compared with baseline values in C and D, and compared with saline in E. LV = left ventricular; EDV = end-diastolic volume; ESV = end-systolic volume; MI = myocardial infarction.

• 

  Figure 4. Myocardial Matrix Modulates the Fibrotic Response in the Infarct Representative Masson’s trichrome staining of saline injected (A) and matrix-injected (B) infarcts (scale bar = 300 μm) at ∼5.5 weeks post-injection. Quantification of infarct fibrosis (C), #p = 0.078.

• 

  Figure 5. Differential Gene Expression Seen at 1 Week Post-Injection of Matrix Heatmap of 42 significantly differentially expressed genes show that gene expression in the matrix treatment group (M1-6) is distinct from the saline control group (S1-6) at 1 week post-injection.